BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 27653425)

  • 1. Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer.
    Tyson MD; Graves AJ; O'Neil B; Barocas DA; Chang SS; Penson DF; Resnick MJ
    JAMA Surg; 2017 Jan; 152(1):27-34. PubMed ID: 27653425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physician variation in management of low-risk prostate cancer: a population-based cohort study.
    Hoffman KE; Niu J; Shen Y; Jiang J; Davis JW; Kim J; Kuban DA; Perkins GH; Shah JB; Smith GL; Volk RJ; Buchholz TA; Giordano SH; Smith BD
    JAMA Intern Med; 2014 Sep; 174(9):1450-9. PubMed ID: 25023650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US.
    Washington SL; Jeong CW; Lonergan PE; Herlemann A; Gomez SL; Carroll PR; Cooperberg MR
    JAMA Netw Open; 2020 Dec; 3(12):e2031349. PubMed ID: 33369661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in use of active surveillance among men undergoing expectant treatment for early stage prostate cancer.
    Filson CP; Schroeck FR; Ye Z; Wei JT; Hollenbeck BK; Miller DC
    J Urol; 2014 Jul; 192(1):75-80. PubMed ID: 24518783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial disparities in changing to a high-volume urologist among men with localized prostate cancer.
    Pollack CE; Bekelman JE; Epstein AJ; Liao K; Wong YN; Armstrong K
    Med Care; 2011 Nov; 49(11):999-1006. PubMed ID: 22005606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population-Based Assessment of Determining Treatments for Prostate Cancer.
    Chamie K; Williams SB; Hu JC
    JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physician social networks and variation in prostate cancer treatment in three cities.
    Pollack CE; Weissman G; Bekelman J; Liao K; Armstrong K
    Health Serv Res; 2012 Feb; 47(1 Pt 2):380-403. PubMed ID: 22092259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist.
    Shahinian VB; Kuo YF; Freeman JL; Goodwin JS
    J Natl Cancer Inst; 2006 Jun; 98(12):839-45. PubMed ID: 16788157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urologist Practice Structure and Spending for Prostate Cancer Care.
    Modi PK; Herrel LA; Kaufman SR; Yan P; Borza T; Skolarus TA; Schroeck FR; Hollenbeck BK; Shahinian VB
    Urology; 2019 Aug; 130():65-71. PubMed ID: 31029672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physician visits prior to treatment for clinically localized prostate cancer.
    Jang TL; Bekelman JE; Liu Y; Bach PB; Basch EM; Elkin EB; Zelefsky MJ; Scardino PT; Begg CB; Schrag D
    Arch Intern Med; 2010 Mar; 170(5):440-50. PubMed ID: 20212180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
    Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
    JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Influence of Practice Structure on Urologists' Treatment of Men With Low-Risk Prostate Cancer.
    Mitchell JM; Gresenz CR
    Med Care; 2022 Sep; 60(9):665-672. PubMed ID: 35880758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer.
    Fowler FJ; McNaughton Collins M; Albertsen PC; Zietman A; Elliott DB; Barry MJ
    JAMA; 2000 Jun; 283(24):3217-22. PubMed ID: 10866869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional-Level Correlations in Inappropriate Imaging Rates for Prostate and Breast Cancers: Potential Implications for the Choosing Wisely Campaign.
    Makarov DV; Soulos PR; Gold HT; Yu JB; Sen S; Ross JS; Gross CP
    JAMA Oncol; 2015 May; 1(2):185-94. PubMed ID: 26181021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancer.
    Shahinian VB; Kuo YF
    BMC Urol; 2015 Apr; 15():25. PubMed ID: 25885745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists.
    Kim SP; Gross CP; Nguyen PL; Smaldone MC; Shah ND; Karnes RJ; Thompson RH; Han LC; Yu JB; Trinh QD; Ziegenfuss JY; Sun M; Tilburt JC
    Med Care; 2014 Jul; 52(7):579-85. PubMed ID: 24926704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Development and Validation of Prostate Cancer-specific Physician-Hospital Networks.
    Jacobs BL; Yabes JG; Lopa SH; Heron DE; Chang CH; Bekelman JE; Nelson JB; Bynum JPW; Barnato AE; Kahn JM
    Urology; 2020 Apr; 138():37-44. PubMed ID: 31945379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.
    Womble PR; Montie JE; Ye Z; Linsell SM; Lane BR; Miller DC;
    Eur Urol; 2015 Jan; 67(1):44-50. PubMed ID: 25159890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expectant management of veterans with early-stage prostate cancer.
    Filson CP; Shelton JB; Tan HJ; Kwan L; Skolarus TA; Saigal CS; Litwin MS
    Cancer; 2016 Feb; 122(4):626-33. PubMed ID: 26540451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urology Workforce Changes and Implications for Prostate Cancer Care Among Medicare Enrollees.
    Marchetti KA; Oerline M; Hollenbeck BK; Kaufman SR; Skolarus TA; Shahinian VB; Caram MEV; Modi PK
    Urology; 2021 Sep; 155():77-82. PubMed ID: 33610652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.